ライフサイエンスコーパス: metalloproteinase

1 of cysteine proteases, serine proteases and metalloproteinases.

2 s required for shedding of its ectodomain by metalloproteinases.

3 modeled in an experience-dependent manner by metalloproteinases.

4 ution of pericytes, immune cells, and matrix metalloproteinases.

5 bsequent activation of intra-alveolar matrix metalloproteinases.

6 ors also show upregulation of certain matrix metalloproteinases.

7 of matrix-degrading and sheddase families of metalloproteinases.

8 , in part, by mechanisms dependent on matrix metalloproteinases.

9 matrix-lytic enzymes, particularly of matrix metalloproteinases.

10 hat act both to sequester and release matrix metalloproteinases.

11 mediators and increased synthesis of matrix metalloproteinases.

12 matory and pro-fibrotic cytokines and matrix metalloproteinases.

13 nd increased circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIMP-3/4 as assessed by

14 otein A [SAA]), inflammatory markers (matrix metalloproteinase 1 [MMP-1] and heme oxygenase 1 [HO-1])

15 tor I (IL-1RI), IL-17R, tissue inhibitors of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2), insulinli

16 growth factor and tissue inhibitor of matrix metalloproteinase 1.

17 pregulated expression of tissue inhibitor of metalloproteinases 1 (TIMP-1), downregulated expression

18 2 (MMP-2), MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2, CD68, and caspase

19 e of the cytokine tissue inhibitor of matrix metalloproteinases 1 (TIMP1) in primary pancreatic tumor

20 receptor 2 or IL-10, and tissue inhibitor of metalloproteinases 1) were identified that, when combine

21 ion-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14.

22 est levels of IFN-alpha, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth fa

23 l cell-derived factor 1; tissue inhibitor of metalloproteinases 1; and vascular cell adhesion molecul

24 RATIONALE: Matrix metalloproteinase-1 (MMP-1) and mast cells are present i

25 One factor, matrix metalloproteinase-1 (MMP-1), is induced in Drosophila en

26 NK)/AP-1 signaling, and expression of matrix metalloproteinase-1 (Mmp1) are activated downstream of D

27 ial growth factor, interleukin-1beta, matrix metalloproteinase-1, versican, and fibronectin.

28 Tissue inhibitor of metalloproteinases-1 (TIMP1) creates a metastasis-suscep

29 affect the secretion of tissue inhibitors of metalloproteinases-1 or -2.

30 A disintegrin and metalloproteinase 10 (ADAM10) is a ubiquitous transmembr

31 and lung fibrosis and that a disintegrin and metalloproteinase 10 (ADAM10) is the major ephrin-B2 she

32 es to endothelial cell growth factor, matrix metalloproteinase 10, and apolipoprotein B-100 in joints

33 the FcepsilonRII sheddase a disintegrin and metalloproteinase 10, which implies that they are import

34 ctive site of the catalytic domain of matrix metalloproteinase-12 (MMP-12 or macrophage metalloelasta

35 ccumulation of macrophages expressing matrix metalloproteinase-12 started manifesting in glomeruli af

36 -induced cytokine, CHI3L1, IL-16, and matrix metalloproteinase-12 were cardiovascular proteins signif

37 ctive inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13).

38 The major metalloproteinase matrix metalloproteinase 13 (MMP13) is also associated with cho

39 lular matrix (ECM) by the collagenase matrix metalloproteinase 13 (MMP13) represents a key event in o

40 Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protea

41 om HIV-negative individuals were stained for metalloproteinase 2 (MMP-2), MMP-3, MMP-9, tissue inhibi

42 Then we identified matrix metalloproteinase 2 (MMP2) as a direct target of CCR4 wh

43 ssential for the proper activation of matrix metalloproteinase 2 (Mmp2) for follicle rupture.

44 actor beta1, collagen type 4 alpha 1, matrix metalloproteinase 2, and alpha-smooth muscle actin) mark

45 evels; increased expression of SNAIL, matrix metalloproteinase 2, and integrin beta1; and increased c

46 llular retinol-binding protein 1, and matrix metalloproteinase 2, compared to term and preterm contro

47 ascular cell adhesion molecule 1, and matrix metalloproteinase 2, were significantly associated with

48 roblast activation markers, including matrix metalloproteinase 2, were significantly increased at the

49 ellular retinol-binding protein 1 and matrix metalloproteinase 2.

50 Tissue inhibitor of metalloproteinases 2 (TIMP2), a blood-borne factor enric

51 d growth factor D, Pdgfrb, Itga2, and matrix metalloproteinases 2 and 9 expression in aortic lesions;

52 a1), connective tissue growth factor, matrix metalloproteinase-2 (MMP-2), MMP-14, endoglin (ENG), and

53 -type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2).

54 nase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).

55 tro, Meg3 regulated the production of matrix metalloproteinase-2 (MMP-2).

56 Reck could suppress the expression of matrix metalloproteinase-2 (Mmp2) and Mmp9, which could activat

57 mitochondrial Ca(2+) uptake promotes matrix metalloproteinase-2 activity and cell motility by ROS-ac

58 and Arfaptin2 leading to secretion of matrix metalloproteinase-2 and -7.

59 Performance of the tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-bindi

60 ristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-bindi

61 reduced nitrosative stress, and lower matrix metalloproteinase-2 expression.

62 re unable to induce OX40 and OX40L by matrix metalloproteinase-2 on splenic dendritic cells.

63 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III N-terminal propept

64 ed fibrosis and altered expression of matrix metalloproteinase-2.

65 in vivo using a fluorescent probe for matrix metalloproteinase-2/9 activity, fluorescein isothiocyana

66 h amelogenin undergoes proteolysis by matrix metalloproteinase 20 (MMP20, enamelysin) soon after secr

67 itate the biomimetic enamel regrowth, matrix metalloproteinase-20 (MMP-20) was introduced into the CS

68 Matrix metalloproteinase-20 (MMP20) is expressed by ameloblasts

69 TWIST1 induced matrix metalloproteinase 3 (MMP3) expression without direct bin

70 prodestructive properties (e.g., IL-6/matrix metalloproteinase 3-release) in response to matrix-assoc

71 CAFs promoted prostate cancer growth, matrix metalloproteinase-3 (MMP-3) was lower in CAFs but elevat

72 of late responsive genes such as the matrix metalloproteinase-3 and the RE1 silencing transcription

73 b inhibition are largely tissue inhibitor of metalloproteinase-3 dependent, while also revealing an a

74 ether miR-181b regulates tissue inhibitor of metalloproteinase-3 expression and affects atheroscleros

75 ely regulates macrophage tissue inhibitor of metalloproteinase-3 expression and vascular smooth muscl

76 ix resulted in the strongest IL-6 and matrix metalloproteinase-3 release, and was even more pronounce

77 dicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

78 dicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

79 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a central inhibitor of

80 ntly decreased levels of tissue inhibitor of metalloproteinases 4 (TIMP-4).

81 rcinoma with a concurrent increase of matrix metalloproteinase 7 (MMP7) expression in mouse prostate.

82 Expression of matrix metalloproteinase 7 (MMP7), an AP-1 target, was also sig

83 rum biomarkers (surfactant protein D, matrix metalloproteinase 7, CA19-9, and CA-125) that were suita

84 eloperoxidase-dependent activation of matrix metalloproteinase 7.

85 RATIONALE: Matrix metalloproteinase-7 (MMP-7) has been implicated in inter

86 truncated N-cadherin), or deletion of matrix-metalloproteinase-7 (Mmp-7) reduced VSMC apoptosis in mo

87 ositional analysis with LC-MS/MS, and matrix metalloproteinase-7 (MMP7) were identified as a potentia

88 array assays revealed that WNT5A and matrix metalloproteinase-7 (MMP7) were upregulated by FOXC1 in

89 l-2 (B-cell lymphoma 2), c-Myc, MMP7 (matrix metalloproteinase-7), and cyclin D1in vitro and in vivo

90 nase inhibitors or antibodies to disintegrin metalloproteinase 8 (ADAM8), a major eosinophil metallop

91 Matrix metalloproteinase 8 (MMP-8) is a proinflammatory enzyme

92 responded with lower plasma levels of matrix metalloproteinase-8 and soluble E-selectin.

93 Inhibition of matrix metalloproteinase-8 improves survival following cecal li

94 ompared with wild-type mice receiving matrix metalloproteinase-8 null marrow, suggesting that matrix

95 In our adoptive transfer experiments, matrix metalloproteinase-8 null mice receiving wild-type marrow

96 no survival advantage was seen among matrix metalloproteinase-8 null mice.

97 Clinically, median matrix metalloproteinase-8 serum concentrations were higher in

98 puncture to test the hypothesis that matrix metalloproteinase-8-containing myeloid cells are a criti

99 einase-8 null marrow, suggesting that matrix metalloproteinase-8-containing myeloid cells are not a c

100 associated with decreased circulating matrix metalloproteinase 9 (MMP-9) and increased circulating ti

101 tions concurrently with expression of matrix metalloproteinase 9 (MMP-9), a marker of fast MNs.

102 Cathepsin B increased the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved in extra

103 a high level of enzymatically active matrix metalloproteinase 9 (MMP-9), and were capable of mediati

104 une skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release fr

105 I were reduced as was the activity of matrix metalloproteinase 9 (MMP-9).

106 Matrix metalloproteinase 9 (MMP9) contributes to this process a

107 Matrix metalloproteinase 9 (MMP9) is a member of a large family

108 Matrix metalloproteinase 9 (MMP9) is expressed in teeth from ea

109 Only matrix metalloproteinase 9 (MMP9) was validated; in pre-PML pat

110 ed levels and activity of circulating matrix metalloproteinase 9 and elevated angiostatin levels in p

111 It is a major inducer of matrix metalloproteinase 9 and is selectively toxic for motor n

112 f the granules' contents, measured as matrix metalloproteinase 9 and neutrophil elastase activity in

113 n, glutathione-synthesizing capacity, matrix metalloproteinase 9 expression and neointimal smooth mus

114 Matrix metalloproteinase 9 testing in DED is a valuable new dia

115 operoxidase, neutrophil elastase, and matrix metalloproteinase 9, activates macrophages through TLRs,

116 m symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 calcium bi

117 Matrix metalloproteinase 9, metalloproteinase inhibitor 1, mono

118 A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and gal

119 HIT activity and enhance secretion of matrix metalloproteinase 9.

120 ctive of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for

121 investigated the possible function of matrix metalloproteinase-9 (MMP-9) in alcohol addiction because

122 ption factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these cells.

123 ollagen deposition, and inhibition of matrix metalloproteinase-9 (MMP-9) secretion.

124 es (VCAM-1 and ICAM-1, respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-alpha

125 cal inhibition or genetic ablation of matrix metalloproteinase-9 (MMP-9).

126 In addition, PKal inhibition reduced matrix metalloproteinase-9 activity in brain following stroke a

127 display helper function for monocyte matrix metalloproteinase-9 and tissue factor production and pro

128 eta2GPI-specific T cells for monocyte matrix metalloproteinase-9 and tissue factor production, as wel

129 ular matrix remodeling is mediated by matrix metalloproteinase-9 expressed in macrophages within the

130 Osteopontin and matrix metalloproteinase-9 were confirmed inside EV.

131 x-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A levels

132 attributed to changes in TGF-beta and matrix metalloproteinase-9, the downstream effectors of TSP-2.

133 volving the PI3K/AKT/mTOR pathway and matrix metalloproteinase-9.

134 aortas from XY females had augmented matrix metalloproteinase activity and increased oxidative stres

135 However, intra-alveolar matrix metalloproteinase activity and levels of the matrix meta

136 We found that matrix metalloproteinase activity is not required for matrix al

137 stood pathogenesis in which increased matrix metalloproteinase activity might play an important role.

138 tive disorders also display increased matrix metalloproteinase activity that contribute to neuronal l

139 tion of EDPs reduced aortic dilation, matrix metalloproteinase activity, and proinflammatory cytokine

140 monstrate that NOTCH1 is a target of ADAMTS1 metalloproteinase activity, which reduces Notch signalin

141 methyl-D-aspartate (NMDA) ratios, and matrix metalloproteinase activity.

142 ve tissue diseases associated with increased metalloproteinase activity.

143 Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer

144 We demonstrate that a disintegrin and metalloproteinase (ADAM)10 is the primary physiological

145 of metalloproteases mainly a disintegrin and metalloproteinase (ADAM)10, ADAM17, ADAM19, and MMP3.

146 igands induced the surface expression of the metalloproteinase ADAM10 on T1 B cells in a Taok3-depend

147 recruitment of the Notch-processing membrane metalloproteinase ADAM10.

148 and the sister families of "adisintegrin and metalloproteinase" (ADAMs), ADAMs with thrombospondin do

149 Here we identify the metalloproteinase ADAMTS1 and inducible nitric oxide syn

150 ies could be detected using an active matrix metalloproteinase (aMMP)-8 chairside test in Finnish ado

151 an unexpected class of proteases, the matrix metalloproteinase and ADAM families, as potential target

152 ns upon interacting with integrins or matrix metalloproteinase and DNA deformations upon protein bind

153 rming growth factor-beta, arginase-1, matrix metalloproteinase and vascular endothelial growth factor

154 d a set of disease markers, including matrix metalloproteinases and activated NF-kappaB, hereby switc

155 on, including increased expression of matrix metalloproteinases and activation of the c-MET tyrosine

156 mmune cells secrete proteases such as matrix metalloproteinases and cathepsins that contribute to dis

157 pithelium, followed by the imbalance between metalloproteinases and their physiological inhibitors (i

158 ns in matrix remodeling proteins (eg, matrix metalloproteinases and tissue inhibitor of metalloprotei

159 The metalloproteinase anthrax lethal factor (LF) is secreted

160 s of C. atrox venom suggest that snake venom metalloproteinases are largely responsible for the impro

161 ators, we identified TGF-beta and the matrix metalloproteinases as therapeutic targets whose modulati

162 proteinase activity and levels of the matrix metalloproteinase cleavage product soluble receptor for

163 rotein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion from fib

164 x metalloproteinases and tissue inhibitor of metalloproteinases) compared with wild-type mice.

165 ors (imbalances in favour of prooxidants and metalloproteinases) contributing to oxidative stress and

166 se cells, including reactive oxygen species, metalloproteinases, cytokines, and antibodies promote dy

167 hila ovulation, a process involving a matrix metalloproteinase-dependent follicle rupture.

168 Thus, matrix metalloproteinase-directed processing of PTHrP disables

169 A disintegrin and metalloproteinase domain-containing protein (ADAM)-10, A

170 Metalloproteinases dynamically regulate cellular behavio

171 Gbetagamma-protein kinase C- and Gbetagamma-metalloproteinase/EGFR-dependent MAPK/ERK signaling casc

172 anchored proteins by ADAM (a disintegrin and metalloproteinase) endopeptidases plays a key role in a

173 ities in fibrillin-1 accumulation and matrix metalloproteinase expression.

174 enzymes (eg, integrin alphavbeta3 and matrix metalloproteinases), have proven effective in preclinica

175 l lysis assay formats, with special focus on metalloproteinases important in metastasis.

176 Furthermore, inhibiting matrix metalloproteinases in ACM reversed ACM's effect on tumor

177 - and TNF-alpha-induced expression of matrix metalloproteinases in both mouse and human chondrocytes.

178 Induction of matrix metalloproteinases in melanoma cells by longwave UVA rad

179 ll bodies, and their ectodomains are shed by metalloproteinases in response to NMDA receptor activati

180 Matrix metalloproteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant

181 ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in accumulat

182 Treatment of microglia with a metalloproteinase inhibitor inhibited LRP1 shedding and

183 , the release of sVLDLR-N was inhibited by a metalloproteinase inhibitor, TAPI-1, while it was promot

184 egulated the expression of TIMP3, a secreted metalloproteinase inhibitor, that inhibited MMP14 to blo

185 ation by augmenting levels of the endogenous metalloproteinase inhibitor, tissue inhibitor of metallo

186 Metalloproteinase inhibitors often feature hydroxamate m

187 Clearance was attenuated by metalloproteinase inhibitors or antibodies to disintegri

188 Actinonin and matlystatins are potent metalloproteinase inhibitors that comprise rare N-hydrox

189 Neprilysins are Type II metalloproteinases known to degrade and inactivate a num

190 The major metalloproteinase matrix metalloproteinase 13 (MMP13) is

191 The cation/Cl(-) cotransporters and ECM metalloproteinases may be particularly druggable targets

192 del, we show that GalNAc-T2 co-regulates the metalloproteinase-mediated limited proteolysis of beta1A

193 loma cells express high levels of the matrix metalloproteinase MMP-13 and determined that MMP-13 dire

194 lz, and socs3, and development genes, matrix metalloproteinases mmp-9 and mmp-13, while cortisol led

195 phosphorylated-FAK, and expression of matrix metalloproteinase (MMP) -2, MMP-9 and vimentin.

196 trix is accompanied by an increase in matrix metalloproteinase (MMP) 13, partially because of enhance

197 endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) 13.

198 rosarcoma oncogene ortholog B (MAFB), matrix metalloproteinase (MMP) 2, and MMP14, respectively; howe

199 ing involves the extracellular enzyme matrix metalloproteinase (MMP) 9.

200 Excessive matrix metalloproteinase (MMP) activity is emerging as a key pr

201 otably, matrix stiffness up-regulates matrix metalloproteinase (MMP) activity, and inhibiting MMPs si

202 e was preceded by rapid activation of matrix metalloproteinase (MMP) at pericyte somata, which was vi

203 selectively inhibit AEP and suppress matrix metalloproteinase (MMP) cleavage, leading to the inhibit

204 Cyp26 deficient embryos, attenuating matrix metalloproteinase (MMP) function can rescue both ventric

205 ssociation between a variant within a Matrix metalloproteinase (MMP) gene member, MMP20, and 11q-dele

206 In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to block endo

207 The design of selective matrix metalloproteinase (MMP) inhibitors that also possess fav

208 by stimulating interleukin (IL)-6 and matrix metalloproteinase (MMP) release.

209 roteases and found that inhibition of matrix metalloproteinase (MMP)- and a disintegrin and metallopr

210 udy, we identified elevated levels of matrix metalloproteinase (MMP)-12 in gingival tissue of patient

211 Matrix metalloproteinase (MMP)-13 is a major contributor to car

212 r (TNF)-alpha, nitric oxide (NO), and matrix metalloproteinase (MMP)-2 and tissue inhibitor of metall

213 Matrix metalloproteinase (MMP)-3 expression in CTGF-delivered t

214 nduced by interferon-gamma (MIG), and matrix metalloproteinase (MMP)-8 in serum and saliva from patie

215 Matrix metalloproteinase (MMP)-8 is a major destructive collage

216 Salivary CSF-1, IL-34, and matrix metalloproteinase (MMP)-8, a biomarker candidate of peri

217 This study evaluates levels of matrix metalloproteinase (MMP)-8, MMP-9, and tissue inhibitor o

218 n the tumor cells negatively affected matrix metalloproteinase (MMP)-9 gene expression.

219 estigate levels of salivary and serum matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO), neutro

220 ing, and suppressed the activation of matrix metalloproteinase (MMP)-9-mediated gelatinolysis.

221 driven by Mtb-dependent secretion of matrix metalloproteinase (MMP)-9.

222 traits, including rounded morphology, matrix metalloproteinase (MMP)-independent migration, and nucle

223 s the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific imaging

224 hrough a 3D extracellular matrix in a matrix metalloproteinases (MMP)-dependent fashion.

225 proteases: plasmin, cathepsin L, and matrix metalloproteinases (MMP-2 and MMP-9).

226 RATIONALE: Macrophage elastase (matrix metalloproteinase [MMP]-12) is a potent protease that co

227 Concentrations of active enzymes (matrix metalloproteinase [MMP]-8, elastase, and sialidase) in G

228 ged expression of lysyl oxidase and a second metalloproteinase, MMP-9, in murine optic gliomas relati

229 ress kinase JNK and production of the matrix metalloproteinase MMP1.

230 model and was associated with a decrease in metalloproteinase (MMP2/MMP9) expression and microphthal

231 eutrophil elastase, legumain, and two matrix metalloproteinases (MMP2 and MMP9), we demonstrated that

232 ion of DHT identified significant changes in metalloproteinases (Mmp3 and -9; P < 0.01), a snail fami

233 y skin disorder where upregulation of matrix metalloproteinases (MMPs) and antimicrobial peptides (AM

234 ogen sulfide (H2S), microRNAs (miRs), matrix metalloproteinases (MMPs) and poly-ADP-ribose-polymerase

235 d reinstatement depends on activating matrix metalloproteinases (MMPs) and selective chemogenetic sti

236 Matrix metalloproteinases (MMPs) are central to cancer developm

237 Matrix metalloproteinases (MMPs) are extracellular proteases th

238 Under pathological conditions, matrix metalloproteinases (MMPs) can disrupt the BBB through th

239 Matrix metalloproteinases (MMPs) contribute to conventional aqu

240 Matrix metalloproteinases (MMPs) contribute to the breakdown of

241 Metalloproteinases (MMPs) contribute to tissue remodelin

242 radation of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential for us

243 Drug candidates against matrix metalloproteinases (MMPs) failed in the clinic in the pa

244 o many of us in the field, working on matrix metalloproteinases (MMPs) has felt like riding a roller

245 he expression and activity of several matrix metalloproteinases (MMPs) in cell lines and in the gastr

246 Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of patholo

247 Matrix metalloproteinases (MMPs) play a key role in abdominal a

248 Matrix metalloproteinases (MMPs) play a key role in many diseas

249 Matrix metalloproteinases (MMPs) play key roles in the developm

250 es in the human body is controlled by matrix metalloproteinases (MMPs), a family of more than 20 homo

251 e levels of neutrophil elastase (NE), matrix metalloproteinases (MMPs), and myeloperoxidase (MPO) in

252 controlled by pro-fibrolytic enzymes, matrix metalloproteinases (MMPs), and pro-fibrotic cytokine, TG

253 Enzymes that modify the ECM, such as matrix metalloproteinases (MMPs), have long been recognised as

254 might be related to downregulation of matrix metalloproteinases (MMPs), i.e., MMP-9 and MMP-2, and up

255 use studies have implicated roles for matrix metalloproteinases (MMPs), particularly macrophage-deriv

256 of fibronectin- and laminin-specific matrix metalloproteinases (MMPs), particularly MMP-3, was signi

257 served molecular mechanisms including matrix metalloproteinases (Mmps), steroid signaling, and adrene

258 Monocytes secrete matrix metalloproteinases (MMPs), which have key roles in local

259 to achieve selectivity against human matrix metalloproteinases (MMPs).

260 Platelets contain and release several matrix metalloproteinases (MMPs).

261 LTP are specifically regulated by different metalloproteinases (MMPs).

262 racellular matrix (ECM) remodeling by matrix metalloproteinases (MMPs).

263 n via the induction and activation of matrix metalloproteinases (MMPs).

264 mponents and their regulators such as matrix metalloproteinases (MMPs).

265 tudy, we evaluated the role of membrane-type metalloproteinases (MT-MMPs) in excitatory synaptogenesi

266 microscopy, we show that the membrane-bound metalloproteinase MT1-MMP is enriched not only at podoso

267 ) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not fully inhi

268 paired trafficking of membrane type 1 matrix metalloproteinase (MT1-MMP) and EGF receptor (EGFR) to t

269 Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a membrane-bound MMP that

270 Membrane type 1 matrix metalloproteinase (MT1-MMP, MMP-14) is a transmembrane c

271 VTCN1 is caused by the active proteolysis by metalloproteinase N-arginine dibasic convertase 1 (NRD1)

272 alloproteinase 8 (ADAM8), a major eosinophil metalloproteinase previously implicated in asthma pathog

273 The ADAM (adisintegrin and metalloproteinase) proteases are involved in ectodomain

274 , we found decreased expression of one major metalloproteinase protein (MMP-2) and unchanged expressi

275 Inhibition of gamma-secretase and metalloproteinase proteolysis in the NOTCH pathway, or s

276 mmatory cells, and macrophage-derived matrix metalloproteinases regulate fibrin and collagen turnover

277 onverting enzyme (TACE; ADAM17, CD156b), the metalloproteinase shedding CD62L, was increased at diagn

278 In contrast, the matrix metalloproteinase/TACE (tumor necrosis factor-alpha-conv

279 of rosacea is unclear, but increased matrix metalloproteinase target tissue activity appears to play

280 C. atrox venom contains snake venom metalloproteinases that cleave fibrinogen into fibrin sp

281 isease with small molecule inhibitors of the metalloproteinases that degrade the cartilage matrix hav

282 oteinase with thrombospondin motifs (ADAMTS) metalloproteinases that mediate tissue damage and perpet

283 r integrin activation and delivery of matrix metalloproteinases: through the upstream recruiter CIB1

284 -2, and upregulation of tissue inhibitors of metalloproteinase (TIMP) -1 and TIMP-2.

285 in levels of HIF-1alpha, tissue inhibitor of metalloproteinase (TIMP)-1 and collagen-I, which were bl

286 9, 12), MPO, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 were analyzed using multianal

287 loproteinase (MMP)-2 and tissue inhibitor of metalloproteinases (TIMP)-2 complex.

288 lloproteinase inhibitor, tissue inhibitor of metalloproteinases (TIMP)-3, through blocking its intera

289 ole in the secretion of tissue inhibitors of metalloproteinases (TIMPs).

290 ure PTHrP1-36 hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP1-17.

291 nflammatory cytokines, chemokines and matrix metalloproteinases, which together facilitated T cell en

292 ith nondeficient ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, me

293 nt release factors such as a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) me

294 ve implicated the protease a disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3)

295 by the TIMP-3 target enzyme, adamalysin-like metalloproteinase with thrombospondin motifs 5.

296 ggrecanases of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family con

297 ADAMTS-4 (a disintegrin-like and metalloproteinase with thrombospondin motifs-4) is a sec

298 The discovery of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif, memb

299 member of the ADAMTS (A Disintegrin-like and Metalloproteinase with Thrombospondin-1 motifs) protein

300 multaneous modulation of TGF-beta and matrix metalloproteinases would be more effective in treating e